NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
Aapro, Matti y Karthaus, Meinolf y Schwartzberg, Lee y Bondarenko, Igor y Sarosiek, Tomasz y Oprean, Cristina y Cardona Huerta, Servando y Hansen, Vincent y Rossi, Giorgia y Rizzi, Giada y Borroni, Maria Elisa y Rugo, Hope (2017) NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Supportive Care in Cancer, 25 (4). pp. 1127-1135. ISSN 0941-4355
|
Texto
63.pdf - Versión Publicada Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (705kB) | Vista previa |
Resumen
Purpose Antiemetic guidelines recommend co-administration of targeted prophylactic medications inhibiting molecular pathways involved in emesis. NEPA is a fixed oral combination of a new NK1 receptor antagonist (RA), netupitant (NETU 300mg), and palonosetron (PALO 0.50 mg), a pharmacologically distinct 5-HT3 RA. NEPA showed superior prevention of chemotherapy-induced nausea and vomiting (CINV) compared with oral PALO in a single chemotherapy cycle; maintenance of efficacy/safety over continuing cycles is the objective of this study. Methods This study is a multinational, double-blind study comparing a single oral dose of NEPA vs oral PALO in chemotherapy-naïve patients receiving anthracycline/ cyclophosphamide-based chemotherapy along with dexamethasone 12 mg (NEPA) or 20 mg (PALO) on day 1. The primary efficacy endpoint was delayed (25–120 h) complete response (CR: no emesis, no rescue medication) in cycle 1. Sustained efficacy was evaluated during the multicycle extension by calculating the proportion of patients with overall (0–120 h) CR in cycles 2–4 and by assessing the probability of sustained CR over multiple cycles. Results Of 1455 patients randomized, 1286 (88 %) participated in the multiple-cycle extension for a total of 5969 cycles; 76 % completed ≥4 cycles. The proportion of patients with an overall CR was significantly greater for NEPA than oral PALO for cycles 1–4 (74.3 vs 66.6 %, 80.3 vs 66.7 %, 83.8 vs 70.3 %, and 83.8 vs 74.6 %, respectively; p ≤ 0.001 each cycle). The cumulative percentage of patients with a sustained CR over all 4 cycles was also greater for NEPA (p < 0.0001). NEPA was well tolerated over cycles. Conclusions NEPA, a convenient, guideline-consistent, fixed antiemetic combination is effective and safe over multiple cycles of chemotherapy.
Tipo de elemento: | Article | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Palabras claves no controlados: | Neurokinin-1 receptor antagonist . NEPA . Netupitant . Palonosetron . CINV . Multiple cycles | |||||||||||||||||||||||||||||||||||||||
Materias: | R Medicina > RC Medicina Interna, Psiquiatría, Neurología | |||||||||||||||||||||||||||||||||||||||
Divisiones: | Medicina | |||||||||||||||||||||||||||||||||||||||
Usuario depositante: | Lic. Josimar Pulido | |||||||||||||||||||||||||||||||||||||||
Creadores: |
|
|||||||||||||||||||||||||||||||||||||||
Fecha del depósito: | 25 Mayo 2020 15:42 | |||||||||||||||||||||||||||||||||||||||
Última modificación: | 25 Mayo 2020 15:42 | |||||||||||||||||||||||||||||||||||||||
URI: | http://eprints.uanl.mx/id/eprint/14551 |
Actions (login required)
![]() |
Ver elemento |